COMMUNIQUÉS West-GlobeNewswire

Transactions under Novonesis’ share buyback program
30/06/2025
Novonesis has now completed the announced share buyback program of B shares worth up to EUR 100 million (DKK 746 million) in total during 2025. As of June 27th, 2025, Novonesis has purchased an accumulated 1,729,099 [...]
IBA – Transparency Notification - Denominator
30/06/2025
June 30 th , 2025 Publication made under article 15 of the law of May 2, 2007 relating to the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market and containing various [...]
IBA – Notification de Transparence - Dénominateur
30/06/2025
30 juin 2025 Publication effectuée en vertu de l’article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes dans des émetteurs dont les actions sont admises à la négociation sur un marché [...]
OSE Immunotherapeutics Publishes Letter to Shareholders
30/06/2025
OSE Immunotherapeutics Publishes Letter to Shareholders NANTES, France, June 30, 2025, 6:00 p.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), announces the publication of its inaugural Letter to [...]
OSE Immunotherapeutics publie une Lettre aux Actionnaires
30/06/2025
OSE Immunotherapeutics publie une Lettre aux Actionnaires NANTES, France, 30 juin 2025, 18 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), annonce la publication de sa première Lettre aux [...]
EUROAPI sells Haverhill site to Particle Dynamics as part of its FOCUS-27 transformation plan
30/06/2025
Press Release Paris – June 30, 2025 – EUROAPI today announced the signing of a share purchase agreement (SPA) for the sale of 100% of EUROAPI UK Ltd, the subsidiary operating its Haverhill manufacturing site, with a [...]
EUROAPI cède le site de Haverhill à Particle Dynamics dans le cadre du plan de transformation FOCUS-27
30/06/2025
Communiqué de presse Paris – Le 30 juin 2025 - EUROAPI annonce ce jour la signature d’un accord (Share Purchase Agreement - SPA) portant sur la cession de 100% des titres de EUROAPI UK Ltd, la filiale exploitant son [...]
Erdem Hospital Launches New Pre-Surgery Education Program for Bariatric Patients
30/06/2025
Photo: Erdem Hospital via FL Communications ISTANBUL, June 30, 2025 (GLOBE NEWSWIRE) -- Erdem Hospital in Istanbul has announced the launch of a new pre-operative education program tailored specifically for bariatric [...]
Portal Biotech Raises $35 Million Series A, Leveraging AI to Deliver the World’s First Full-Length Single-Molecule Protein Sequencer
30/06/2025
Breakthrough proteomics platform technology unlocks full-length protein sequencing and characterisation, accelerating drug development and diagnostics LONDON, June 30, 2025 (GLOBE NEWSWIRE) -- Portal Biotech, a [...]
Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat
30/06/2025
– The Launch-HTN trial is the largest trial of an aldosterone synthase inhibitor completed in participants with uncontrolled or treatment resistant hypertension – – Lorundrostat 50 mg once daily demonstrated clinically [...]
Total number of shares and voting rights in Zealand Pharma as of June 30, 2025
30/06/2025
Company announcement – No. 16 / 2025 Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Copenhagen, Denmark, June 30, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: [...]
Acentra Health Earns Fourth Consecutive Recognition on the Washington Business Journal’s Annual ‘Largest Private Companies’ List
30/06/2025
Strategic investments in its solutions and workforce fuel the company’s consistent growth in WBJ’s rankings, earning the No. 43 spot in 2025 MCLEAN, Va., June 30, 2025 (GLOBE NEWSWIRE) -- Acentra Health , a technology [...]
Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes
30/06/2025
WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
Completion of Share Buy-back Program
30/06/2025
Company Announcement COPENHAGEN, Denmark; June 30, 2025 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2025. On March 25, 2025, Genmab announced the initiation of a [...]
Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder
30/06/2025
Vancouver, Canada, June 30, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]
Senti Bio Participates in Nasdaq Amplify Spotlight Series
30/06/2025
Access the segment here SOUTH SAN FRANCISCO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next- [...]
GCANRx Announces Uplisting to New Market Tier
30/06/2025
BALTIMORE, June 30, 2025 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics and [...]
INVO Fertility Adds Platelet-Rich Plasma Therapy Capabilities at Wisconsin Fertility Institute
30/06/2025
MIDDLETON, Wis. and SARASOTA, Fla., June 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare company focused on the fertility market, is excited to announce [...]
Windtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim Analysis
30/06/2025
The SEISMiC C Study is the third study in the istaroxime cardiogenic shock development program - SEISMiC C is studying more severely ill SCAI Stage C cardiogenic shock patients Windtree has previously reported two [...]

Pages